ISU Abxis, a subsidiary of the ISU conglomerate, is a biotech company with a focus on orphan drugs and rare disease. CEO Seok Joo Lee explains the rationale behind his decision to transform ISU Abxis’ international strategy from targeting developing markets to aiming for developed Western markets, such as the USA. He also offers an insight into the complexity of finding the appropriate expertise when developing orphan drugs for rare diseases.
While there is a lot of potential to develop first in class products within blue ocean markets, one of the major issues is that there is a lack of scientific literature and research, making collaboration with the right key opinion leaders imperative
